Clinic-Ready Insights on Emerging Data for Current Antibody–Drug Conjugates in Breast Cancer

Deepen your understanding on the mechanisms of action, efficacy, and guideline recommendations for using antibody–drug conjugates to treat breast cancer. This program also includes strategies to integrate patients’ treatment goals and preferences into care plans as well as to help manage therapy-related toxicities through an expert-written ClinicalThought and an on-demand webcast with accompanying downloadable slides.

Share

Program Content

Activities

  • Breast Cancer ADC Essentials
    Background on the Targets, Structures, and Mechanisms of ADCs Approved for Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2025

    Expires: September 12, 2025

  • Latest Evidence With the Breast Cancer ADCs
    Current ADC Indications and Data From Clinical Trials and Real-World Cohorts
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 13, 2025

    Expires: September 12, 2025

  • Breast Cancer ADC Safety Considerations
    Optimizing Safety and Quality of Life in Patients Receiving ADCs for Breast Cancer
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 14, 2025

    Expires: September 13, 2025

Supporters

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.